1. SVIP is a molecular determinant of lysosomal dynamic stability, neurodegeneration and lifespan.
- Author
-
Johnson, Alyssa E, Orr, Brian O, Fetter, Richard D, Moughamian, Armen J, Primeaux, Logan A, Geier, Ethan G, Yokoyama, Jennifer S, Miller, Bruce L, and Davis, Graeme W
- Subjects
Lysosomes ,Animals ,Animals ,Genetically Modified ,Humans ,Drosophila melanogaster ,Osteitis Deformans ,Muscular Dystrophies ,Limb-Girdle ,Myositis ,Inclusion Body ,Amyotrophic Lateral Sclerosis ,Neurodegenerative Diseases ,Disease Models ,Animal ,Phosphate-Binding Proteins ,Drosophila Proteins ,Membrane Proteins ,Protein Binding ,Longevity ,Mutation ,Frontotemporal Dementia ,Valosin Containing Protein ,Genetically Modified ,Muscular Dystrophies ,Limb-Girdle ,Myositis ,Inclusion Body ,Disease Models ,Animal - Abstract
Missense mutations in Valosin-Containing Protein (VCP) are linked to diverse degenerative diseases including IBMPFD, amyotrophic lateral sclerosis (ALS), muscular dystrophy and Parkinson's disease. Here, we characterize a VCP-binding co-factor (SVIP) that specifically recruits VCP to lysosomes. SVIP is essential for lysosomal dynamic stability and autophagosomal-lysosomal fusion. SVIP mutations cause muscle wasting and neuromuscular degeneration while muscle-specific SVIP over-expression increases lysosomal abundance and is sufficient to extend lifespan in a context, stress-dependent manner. We also establish multiple links between SVIP and VCP-dependent disease in our Drosophila model system. A biochemical screen identifies a disease-causing VCP mutation that prevents SVIP binding. Conversely, over-expression of an SVIP mutation that prevents VCP binding is deleterious. Finally, we identify a human SVIP mutation and confirm the pathogenicity of this mutation in our Drosophila model. We propose a model for VCP disease based on the differential, co-factor-dependent recruitment of VCP to intracellular organelles.
- Published
- 2021